Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ORIC
SellSinkerORIC Pharmaceuticals, Inc. · Healthcare · United States · $1.4B · Avg Vol: $16M/d
COMPANY DESCRIPTION
ORIC Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapies that overcome resistance in cancer. The company targets critical mechanisms of therapeutic resistance in oncology, addressing a significant unmet medical need through its proprietary pipeline. ORIC is a specialized oncology biotech firm, aiming to develop first-in-class or best-in-class treatments by precisely targeting cancer resistance pathways.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -2.07 | -0.98 | -1.96 | -1.83 | -1.47 | — | -1.30 | -1.48 | -1.61 | — |
| Shares | — | 103.5M | 54.9M | 71.0M | 98.5M | -4.8% | 103.7M | — | — | — |
| Debt | — | 2.7M | 2.8M | 3.2M | 3.3M | 7.8% | 6.0M | — | — | — |
| Equity | — | 222.4M | 224.1M | 243.1M | 384.4M | 20.0% | — | — | — | — |
| Op CF | — | -75.1M | -85.7M | -112.7M | -111.0M | — | -111.6M | — | — | — |
| Inv CF | — | -109.2M | -43.4M | 22.1M | -148.0M | — | — | — | — | — |
| Fin CF | — | 25.2M | 85.7M | 126.5M | 245.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ORIC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ORIC | ORIC Pharmaceuticals, Inc.(you) | $1.4B | 22 | Sell |
| JBIO | Jade Biosciences, Inc. | $1.3B | 24 | Sell |
| VOR | Vor Biopharma Inc. | $1.3B | 20 | Sell |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | 22 | Sell |
| CGEM | Cullinan Therapeutics, Inc. | $1.3B | 26 | Sell |
| MNKD | MannKind Corporation | $1.3B | 25 | Sell |
| REPL | Replimune Group, Inc. | $1.5B | 19 | Strong Sell |
| KURA | Kura Oncology, Inc. | $1.1B | 23 | Sell |
| ABSI | Absci Corporation | $1.5B | 17 | Strong Sell |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 20 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%